IGF-1 DES
What the Research Actually Shows
Human: 0 studies, 4 groups · Animal: 3 · In Vitro: 1
The truncated IGF-1 variant your brain actually makes — and why finding it in colostrum doesn't mean injecting it into your deltoid is safe
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
IGF-1 DES is a short version of a natural growth factor with three amino acids chopped off the front. That small change prevents the body's binding proteins from grabbing it, making it roughly 2.5 times more powerful than regular IGF-1. Unlike its longer-acting cousin LR3, DES acts fast — roughly 20 to 30 minutes — which is why bodybuilders inject it directly into muscles right after a workout. The surprising part: your brain and breast milk actually contain trace amounts of this exact molecule. But no one has ever studied what happens when you inject it at bodybuilding doses. Zero human trials exist. If you use IGF-1 DES, you are generating the only human data there is.
IGF-1 DES — formally des(1-3)IGF-1 — is a 67-amino-acid truncated form of human insulin-like growth factor-1, missing the first three N-terminal residues (Gly-Pro-Glu). Those three amino acids are precisely the residues that IGF binding proteins use to sequester IGF-1, so their absence produces a molecule that circulates essentially free and activates the IGF-1 receptor with approximately 2.5 times the potency of native IGF-1 in animal models (PMID 2280209).
What distinguishes IGF-1 DES from its engineered sibling LR3 is pharmacokinetics: DES has an estimated half-life of 20–30 minutes compared to LR3's 20–30 hours. This short systemic window has made it the community's preferred variant for localized, site-specific muscle injection — the theory being that a compound cleared in minutes exposes the whole body to less cumulative growth factor signaling than one that persists for a day.
The other distinctive feature is endogenous origin. Unlike LR3, which is entirely engineered, des(1-3)IGF-1 has been detected in human brain tissue and bovine colostrum. It is a naturally occurring truncated form — though "naturally occurring in trace amounts in brain tissue" is a long journey from "safe to inject in milligram quantities into skeletal muscle."
This article examines the preclinical evidence for IGF-1 DES, its relationship to IGF-1 LR3 and native IGF-1, and the honest assessment of what is known and what is assumed about a compound no human has ever been studied using.
In This Article
Quick Facts: IGF-1 DES at a Glance
Type
Truncated IGF-1 variant (67 amino acids)
Also Known As
des(1-3)IGF-1, des(1-3)IGF-I, truncated IGF-1, DES IGF-1
Generic Name
des(1-3)IGF-1 (no INN assigned)
Brand Name
None — no pharmaceutical product exists
Related Compounds
IGF-1 LR3 (engineered variant, long-acting), native IGF-1/mecasermin (Increlex), MGF (IGF-1Ec splice variant E-peptide)
Molecular Weight
~7,372 Da
Peptide Sequence
67 amino acids: native IGF-1 (70 AA) minus first three N-terminal residues (Gly-Pro-Glu)
Endogenous Origin
Partially endogenous — detected in human brain tissue and bovine colostrum, but not a major circulating form
Primary Molecular Function
IGF-1R agonist with near-total IGFBP evasion; activates PI3K/Akt/mTOR and Ras/MAPK pathways
Active Fragment
Full truncated molecule is the active form; N-terminal truncation eliminates IGFBP binding
Half-Life
Estimated 20–30 minutes (much shorter than LR3; closer to native IGF-1 kinetics)
Clinical Programs
None for DES. Native IGF-1 (mecasermin) is FDA-approved for severe IGF-1 deficiency
Route
Intramuscular injection site-specific (preferred community route); subcutaneous injection
Community Interest
Localized muscle growth, site-specific hypertrophy, post-workout recovery. Preferred over LR3 for targeted injection protocols
FDA Status
Not approved. Not a pharmaceutical product. Never submitted for regulatory review
WADA Status
Prohibited under S2: Peptide Hormones, Growth Factors, Related Substances. Detection methods available (PMID 33587816)
Evidence Tier
4 Preclinical Only
Verdict
Eyes Open
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is IGF-1 DES?
Pronunciation: IGF-one DES (1,3)
Somewhere in the first moments after birth, a newborn's gut encounters something remarkable in breast milk: trace amounts of a growth factor variant called des(1-3)IGF-1 — a truncated version of insulin-like growth factor-1 that is missing three amino acids from its front end. This isn't a manufacturing error or a degradation product. It's a naturally occurring form that has also been detected in human brain tissue, suggesting it may play a role in neural development.
Those three missing amino acids — glycine, proline, and glutamate — happen to be the exact residues that the body's six IGF binding proteins use to grab and control IGF-1. Remove them, and you get a growth factor that binding proteins cannot sequester. The result: a molecule that delivers its growth signal approximately 2.5 times more potently than native IGF-1, as demonstrated in the foundational 1990 Francis et al. study using growth-deficient mice (PMID 2280209).
The bodybuilding community discovered IGF-1 DES through the same research chemical channels that supply LR3. But where LR3 persists in the body for 20–30 hours, DES is cleared in roughly 20–30 minutes. This pharmacokinetic difference is the entire reason DES has its own community: users inject it directly into target muscles immediately after training, relying on the short half-life to concentrate the growth signal locally before systemic clearance.
PLAIN ENGLISH
IGF-1 DES is like a sprint version of a growth signal — it hits hard and fast, then it's gone. Bodybuilders use this feature to inject it right into the muscles they just trained, hoping the signal stays local. Whether that actually works is something no one has tested in a controlled study.
Origins and Discovery
The discovery of des(1-3)IGF-1 predates its adoption by the performance community by decades. The truncated form was first identified in human brain extracts, where researchers found that the predominant IGF-1 species in neural tissue was not the standard 70-amino-acid form but rather a shorter variant missing the N-terminal tripeptide. Sara et al. detected the truncated form in human fetal brain and adult cerebrospinal fluid, suggesting it plays a role in neural IGF-1 signaling that is distinct from systemic, IGFBP-regulated signaling.
The compound was subsequently identified in bovine colostrum, adding to the evidence that des(1-3)IGF-1 is a biologically relevant form — not an artifact of tissue processing. Francis et al. (1990) then used it alongside LR3-IGF-1 as a tool to study IGF-1 activity independent of IGFBP regulation, establishing the ~2.5x potency enhancement that later attracted community interest (PMID 2280209).
The pathway from brain biology discovery to bodybuilding compound followed the same route as LR3: research chemical vendors making synthetic versions available to anyone willing to accept the "not for human consumption" label.
Mechanism of Action
Receptor Signaling: Identical to Native IGF-1
IGF-1 DES activates the type 1 IGF receptor (IGF-1R) with similar affinity to native IGF-1, triggering the same two major downstream cascades:
PI3K/Akt/mTOR pathway: Protein synthesis, anti-apoptosis, cell survival. This is the primary anabolic cascade — it drives translation of mRNA into contractile and structural muscle proteins (PMID 32858949).
Ras/MAPK/ERK pathway: Cell proliferation, satellite cell activation, myoblast differentiation. This cascade promotes muscle stem cell entry into the cell cycle and subsequent fusion with existing muscle fibers.
PLAIN ENGLISH
DES flips the same two growth switches as regular IGF-1 and LR3. One switch builds protein. The other switch wakes up muscle stem cells. The difference isn't what DES does at the receptor — it's what happens before it gets there.
The IGFBP Evasion: Same Trick, Different Method
Where LR3 achieves IGFBP evasion through an N-terminal extension plus a point mutation, DES achieves it by simply removing the three residues that IGFBPs need for binding. The result is pharmacologically equivalent — both variants circulate essentially free, delivering their full dose as bioavailable receptor agonist.
The critical difference is half-life. DES's smaller size (~7.4 kDa vs. LR3's ~9.1 kDa) and the absence of the protective N-terminal extension result in rapid renal clearance and peptidase degradation. The estimated ~20–30 minute half-life means DES produces a sharp, brief spike of IGF-1R activation followed by rapid clearance.
The Site-Specific Injection Rationale
The community protocol for DES — intramuscular injection directly into target muscles post-workout — is based on a pharmacokinetic hypothesis: if the compound acts quickly and is cleared quickly, most of the growth signal will be delivered to the injection site before systemic distribution. This is plausible but untested. No study has measured local vs. systemic IGF-1R activation after intramuscular DES injection, and the assumption that a 20–30 minute half-life is short enough to prevent significant systemic exposure is unverified.
PLAIN ENGLISH
The idea behind injecting DES into specific muscles is sound in theory — deliver the growth signal locally before it spreads everywhere. But nobody has actually measured whether it works this way. The compound might redistribute faster than assumed, or the growth signal at the injection site might not be meaningfully higher than elsewhere.
Mechanistic Comparison
vs. IGF-1 LR3: Same IGFBP evasion, same receptor, dramatically different half-life (minutes vs. hours). LR3 provides prolonged systemic exposure; DES provides brief, intense exposure. Community users choose based on whether they want systemic or localized effects.
vs. native IGF-1 (mecasermin): DES is unregulated by IGFBPs; mecasermin is fully regulated. Mecasermin has a well-characterized dose-response and safety profile from clinical use. DES has neither.
vs. GH secretagogues: GH secretagogues increase endogenous IGF-1 production through the natural axis, fully IGFBP-regulated. DES bypasses the entire system. Lower potency ceiling with secretagogues but within evolved control mechanisms.
Gut Trophic Effects
An additional mechanism of interest: Lemmey et al. (1991) demonstrated that des(1-3)IGF-1 enhanced intestinal growth after gut resection in rats (PMID 1996625). This suggests potential applications in gastrointestinal repair, though this line of research has not been developed clinically.
Key Research Areas and Studies
Foundational Potency Data
The core pharmacological claim for IGF-1 DES rests on the same study that established LR3's potency. Francis et al. (1990) tested des(1-3)IGF-1 alongside LR3-IGF-1 and native IGF-1 in lit/lit mice (growth hormone–deficient, IGF-1-dependent for growth). Both IGFBP-resistant variants showed approximately 2.5-fold greater growth-promoting activity than native IGF-1 as measured by total body length and weight gain (PMID 2280209).
This result has been internally consistent: IGFBP-resistant IGF-1 variants consistently outperform native IGF-1 in growth-deficient animal models. The pharmacology is clear and reproducible.
PLAIN ENGLISH
The foundational study showed DES works about 2.5 times better than regular IGF-1 in mice that can't make their own growth hormone. That's solid science — but those mice are not healthy human bodybuilders with normal hormone levels.
Anabolic Effects in Catabolic States
Tomas et al. (1992) demonstrated enhanced anabolic effects of IGFBP-resistant IGF-1 variants (including des(1-3)IGF-1) in dexamethasone-treated catabolic rats. The compound increased protein synthesis while decreasing protein breakdown (PMID 1371669). The relevance to healthy humans seeking additional muscle growth beyond their baseline is limited — counteracting drug-induced catabolism is a different physiological scenario.
Gut Trophic Activity
Lemmey et al. (1991) showed that des(1-3)IGF-1 and LR3-IGF-1 enhanced intestinal growth after small bowel resection in rats (PMID 1996625). This is a genuinely interesting finding that distinguishes DES from other performance-oriented compounds — it suggests potential therapeutic applications in short bowel syndrome or post-surgical gut recovery. However, this line of research never progressed to human trials.
PLAIN ENGLISH
One of the most interesting findings about DES has nothing to do with muscle — it helped rats regrow gut tissue after surgery. This could have real medical applications, but nobody has followed up on it in humans.
Anti-Doping Detection
Thomas et al. (2021) developed HRMS detection methods for both des(1-3)IGF-1 and LR3-IGF-1, confirming that DES is detectable in anti-doping testing (PMID 33587816). The same study documented quality concerns with commercial products.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “"IGF-1 DES is 2.5x more potent than regular IGF-1"” | Francis et al. (1990) confirmed ~2.5x greater growth activity in lit/lit mice (PMID 2280209). Accurate in growth-deficient animal models. | Supported |
| “"DES promotes site-specific muscle growth when injected locally"” | The pharmacokinetic rationale (short half-life → localized effect) is plausible but untested. No study has measured local vs. systemic IGF-1R activation after IM DES injection. | Theoretical |
| “"DES is safer than LR3 because it clears faster"” | The shorter half-life means less total systemic IGF-1R exposure per dose, which theoretically reduces cumulative cancer risk. But this has never been measured or validated. Both compounds carry the same fundamental risk of unregulated growth factor signaling. | Theoretical |
| “"DES builds muscle in humans"” | Zero human clinical trials exist. No human has been studied using IGF-1 DES for any purpose. | Preclinical Only |
| “"DES is natural — it's found in breast milk and brain tissue"” | True — des(1-3)IGF-1 has been detected in human brain tissue and bovine colostrum. But endogenous presence in trace amounts does not establish that exogenous injection at bodybuilding doses is safe or effective. | Mixed Evidence |
| “"Inject DES into target muscles immediately post-workout"” | Community protocol with zero published basis. No dose-response, timing, or localization study exists for this use case. | Unsupported |
| “"50–100 mcg per injection site is the right dose"” | Entirely community-derived. No published dose-finding study in any species for this specific compound at these doses for muscle growth. | Unsupported |
| “"DES is the best IGF-1 variant for localized muscle growth"” | Plausible based on the short half-life, but "best" implies comparison data that doesn't exist. No study has compared DES, LR3, and native IGF-1 for localized muscle effects. | Theoretical |
| “"The cancer risk from DES is minimal because of the short half-life"” | Reduced cumulative exposure time per dose is theoretically protective. But cancer development from IGF-1R stimulation is cumulative over cycles and years. No longitudinal safety data exists. | Theoretical |
| “"DES helps with gut healing"” | Lemmey et al. (1991) showed enhanced intestinal growth after gut resection in rats (PMID 1996625). This is genuine preclinical evidence for a specific indication — but it's animal data, not human. | Preclinical Only |
| “"You can use DES and LR3 together for different effects"” | Community stacking protocol with no published basis. Combining two unregulated IGF-1R agonists with different pharmacokinetic profiles produces an unpredictable cumulative exposure. | Unsupported |
| “"Research chemical DES is pure and reliable"” | Thomas et al. (2021) found quality concerns across IGF-1 variant products (PMID 33587816). No pharmaceutical-grade DES exists. | Unsupported |
We currently don’t have any vetted partners for this compound. Check back soon.
The Human Evidence Landscape
There is no human evidence for IGF-1 DES. Zero clinical trials. Zero published case reports. Zero systematic observations. The compound has never been administered to a human subject in any controlled research setting.
The closest human data comes from two entirely different molecules: - Recombinant native IGF-1 (mecasermin): FDA-approved for IGF-1 deficiency. Fully IGFBP-regulated. Different pharmacokinetics, different dose-response, different safety profile. - Endogenous des(1-3)IGF-1 detected in brain tissue and colostrum: Confirms the truncated form exists naturally but at trace concentrations in specific tissues — not as a systemically administered pharmacological agent.
What Would Need to Happen for Human Evidence to Emerge
The same barriers apply as for LR3: GMP production, pre-IND toxicology, FDA approval of an IND, and Phase I dose-finding. The shorter half-life of DES might make it slightly more attractive for clinical development (easier to manage adverse events with a quickly cleared compound), but no pharmaceutical company has expressed interest. The existence of FDA-approved mecasermin removes the commercial incentive.
An alternative development pathway might exist through the gut trophic effects — DES could theoretically be investigated for short bowel syndrome or post-surgical intestinal recovery. But this indication would require oral or enteral formulation research that has not been pursued.
PLAIN ENGLISH
Nobody has studied IGF-1 DES in humans, and nobody is working on studying it. The compound exists in a regulatory void — too risky for drug development when safer alternatives exist, too niche for academic interest. If you use it, you are the data.
Safety, Risks, and Limitations
Hypoglycemia
Same mechanism as LR3: IGF-1R activation produces insulin-like glucose-lowering effects. The risk may be modulated by DES's shorter half-life — a brief hypoglycemic episode rather than sustained glucose suppression — but this has not been characterized. Post-workout injection (when glycogen stores are already depleted) may amplify the risk.
CRITICAL DISCLAIMER
Injecting IGF-1 DES immediately after training — when glycogen is already depleted and blood glucose may already be low — could compound the hypoglycemic risk. Keep fast-acting carbohydrates available.
Cancer Risk
Same mechanistic basis as LR3: potent, unregulated IGF-1R stimulation promotes cell proliferation and inhibits apoptosis. The shorter half-life theoretically reduces cumulative exposure per dose, but cancer development is a function of total lifetime exposure across all cycles, not just per-dose exposure.
PLAIN ENGLISH
A shorter half-life means each injection exposes your body to the growth signal for less time. But if you inject DES five days a week for years, the total exposure adds up. Cancer risk from growth factor signaling is a marathon, not a sprint.
Local Injection Risks
Intramuscular injection carries site-specific risks: infection, nerve damage, intramuscular hematoma, and potential for localized tissue overgrowth. The site-specific injection protocol also assumes the user can accurately target the intended muscle — improper injection technique could deliver the compound to surrounding tissues, vasculature, or nerves.
Product Quality
The same concerns documented for LR3 apply to DES: no pharmaceutical-grade product, research chemical manufacturing standards, and documented degradation in commercial products (PMID 33587816). DES's smaller size (67 amino acids vs. LR3's 83) may make it somewhat easier to synthesize correctly, but this advantage is marginal in the absence of quality control standards.
Short Half-Life Double-Edged Sword
The rapid clearance that makes DES attractive for site-specific injection also means that adverse effects (particularly hypoglycemia) may have a shorter duration. However, the peak concentration at the injection site will be higher for a given dose — the same total effect compressed into a shorter window means a more intense acute response.
Legal and Regulatory Status
IGF-1 DES is not approved by the FDA for any indication. It has never been submitted for regulatory review and is not a pharmaceutical product. It is sold as a research chemical with "not for human consumption" labeling.
WADA prohibits des(1-3)IGF-1 under category S2 (Peptide Hormones, Growth Factors, Related Substances). Validated detection methods exist (PMID 33587816).
The compound occupies an identical legal position to IGF-1 LR3: available for purchase as a research reagent, not legally marketed for human use, and without any consumer protection for purity, potency, or safety.
Research Protocols and Formulation Considerations
No published research protocol exists for human administration of IGF-1 DES. All dosing and administration information derives from community experience.
Like LR3, DES is typically supplied as a lyophilized powder requiring reconstitution with bacteriostatic water. The reconstituted solution should be stored at 2–8°C (35–46°F). DES's shorter half-life has no bearing on storage stability — the compound degrades at the same rate as other peptides when in solution.
As a 67-amino-acid protein, DES is moderately complex. It is smaller than LR3 (83 amino acids) but substantially larger than most community peptides (5–15 amino acids). Proper folding is essential for receptor binding — degraded or misfolded DES may have reduced or absent biological activity.
Dosing in Published Research
WHY NO DOSING CHART?
No published dose-response study exists for IGF-1 DES. The doses reported in the research literature were used in specific experimental contexts, not established through systematic dose-optimization trials. Without controlled data comparing different doses, routes, or durations, we cannot responsibly present a clinical dosing table. What the published studies used is described in the text below.
No published dose-response study exists for IGF-1 DES in any species for the purpose of muscle growth or body composition enhancement.
Published animal dosing: Francis et al. (1990) used des(1-3)IGF-1 at comparable molar doses to LR3-IGF-1 and native IGF-1 in lit/lit mice, achieving measurable growth effects (PMID 2280209). Lemmey et al. (1991) used des(1-3)IGF-1 for gut trophic effects in rats after bowel resection (PMID 1996625). Neither study provides a basis for human dosing extrapolation.
Dosing in Self-Experimentation Communities
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
WHY IS THIS SECTION NEARLY EMPTY?
IGF-1 DES has limited community usage data. Unlike more widely-used research peptides, there are few reliable community reports on dosing protocols. We include this section for completeness but cannot populate it with data we do not have. As community experience grows, we will update this section accordingly.
The following table summarizes community-reported dosing practices for IGF-1 DES. These are not clinical recommendations. No controlled trial data supports these protocols.
| Route | Community Use | Evidence | Dose (Range) | Key Risks |
|---|---|---|---|---|
| Intramuscular (site-specific) | Preferred route — inject into target muscle post-workout | No published evidence | 50–100 mcg per injection site, bilateral | Localized tissue overgrowth, infection, nerve damage, systemic spillover |
| Subcutaneous | Less common; used when site-specific targeting isn't desired | No published evidence | 50–100 mcg/day | Hypoglycemia, systemic IGF-1R stimulation |
| Timing (post-workout) | Standard community protocol | No published evidence | Inject within 30 min of training | Amplified hypoglycemia risk on depleted glycogen |
Community protocols typically involve 4–6 week cycles paired with training. DES is frequently combined with LR3 (DES for localized effects post-workout, LR3 for systemic effects on off days) — a stacking protocol with zero published basis.
PLAIN ENGLISH
Every number in the table above — the dose, the timing, the cycle length — comes from forums and community experience. None of it has been tested in a study. The injection-into-specific-muscles protocol is based on logic, not data.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into IGF-1 DES combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining IGF-1 DES with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
| Compound | Type | Evidence Tier | Verdict | Mechanism | Primary Use Case | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|
| IGF-1 LR3 | 83-AA engineered IGF-1 variant (long-acting) | Tier 4 — Preclinical Only | Eyes Open | IGF-1R → PI3K/Akt/mTOR; evades IGFBPs via Arg3→Glu substitution in E-extension; ~2.5× potency of native IGF-1 | Muscle hypertrophy; fat loss; recovery | None — zero human studies | Not approved | Prohibited (S2 — Peptide Hormones, Growth Factors) | Zero human data; same mitogenic pathway that drives cancer; product authenticity variable |
| IGF-1 DES | 67-AA truncated IGF-1 variant (short-acting) | Tier 4 — Preclinical Only | Eyes Open | IGF-1R → PI3K/Akt/mTOR; lacks N-terminal tripeptide → cannot bind IGFBPs; ~10× IGF-1R affinity; rapid clearance (~20–30 min) | Local muscle growth (site injection); fat loss | None — zero human studies | Not approved | Prohibited (S2 — Peptide Hormones, Growth Factors) | Zero human data; extremely short half-life requires precise timing; same cancer-risk axis as LR3 |
| MGF / PEG-MGF | 24-AA E-peptide from IGF-1Ec splice variant (± PEG) | Tier 4 — Preclinical Only | Thin Ice | Proposed: satellite cell activation via E-peptide signaling independent of IGF-1R; PEG extends half-life. Disputed — one key study showed no effect on myoblasts | Muscle repair; satellite cell activation; recovery | None — zero human studies | Not approved | Prohibited (S2 — Peptide Hormones, Growth Factors) | Free MGF E-peptide never isolated from biological fluids; fundamental bioactivity disputed; key negative study (PMID 24253050) |
| Follistatin | 344-AA glycoprotein (~35–40 kDa) | Tier ~ — It's Complicated | Eyes Open | Binds and neutralizes myostatin (GDF-8) + activins → derepression of Smad 2/3 → satellite cell activation → muscle hypertrophy | Muscle growth (myostatin blockade); muscular dystrophy gene therapy | 6 patients in 1 open-label gene therapy trial (Becker MD) | Not approved (IND for gene therapy) | Prohibited (S4.5 — Myostatin Inhibitors) | Human data is gene therapy only — not injectable protein; complex glycoprotein hard to manufacture correctly; broader myostatin inhibitor clinical programs have failed |
Frequently Asked Questions
What is the difference between IGF-1 DES and IGF-1 LR3?
Both evade the body's IGF binding proteins and are approximately 2.5 times more potent than native IGF-1. The key difference is half-life: DES is cleared in approximately 20–30 minutes, while LR3 persists for approximately 20–30 hours. This makes DES preferred for site-specific muscle injection, while LR3 is used for systemic effects. Additionally, DES is a naturally occurring truncated form (detected in brain tissue and colostrum), while LR3 is entirely engineered.
Has IGF-1 DES been tested in humans?
No. Zero published human clinical trials exist for des(1-3)IGF-1 for any indication, any route, or any dose.
Is IGF-1 DES natural?
Partially. des(1-3)IGF-1 has been detected in human brain tissue and bovine colostrum. It appears to be a naturally occurring truncated form of IGF-1, not solely a synthetic creation. However, endogenous presence in trace amounts does not establish that exogenous injection at bodybuilding doses is safe.
Does injecting DES into a specific muscle actually cause localized growth?
The pharmacokinetic rationale is plausible — a compound with a 20–30 minute half-life injected directly into muscle may deliver most of its signal locally before systemic clearance. But this has never been measured. No study has compared local vs. systemic IGF-1R activation after intramuscular DES injection.
Is DES safer than LR3 because it clears faster?
The shorter half-life means less total systemic exposure per dose, which theoretically reduces the cumulative cancer risk per injection. But safety is determined by total lifetime exposure, and community protocols involve repeated injections over multiple cycles. "Safer per dose" does not mean "safe."
What is the cancer risk from IGF-1 DES?
Same mechanistic basis as all IGF-1 axis compounds: potent IGF-1R stimulation promotes cell proliferation and inhibits apoptosis. The short half-life modestly reduces per-dose exposure, but cumulative cancer risk depends on total exposure across all cycles and years of use.
Can I use DES and LR3 together?
Community protocols combine DES (post-workout, localized) with LR3 (systemic, on off-days or morning). This stacking approach has no published basis. Combining two unregulated IGF-1R agonists produces unpredictable cumulative exposure and compounds both the anabolic effects and the cancer risk.
What dose of IGF-1 DES should I use?
No published dose-finding study exists. Community protocols typically use 50–100 mcg per injection site. These numbers are entirely empirical — there is no published basis for any specific dose.
Why would DES be interesting for gut health?
Lemmey et al. (1991) showed that des(1-3)IGF-1 enhanced intestinal growth after surgical gut resection in rats (PMID 1996625). This suggests potential for gastrointestinal repair applications, but no human trial has explored this.
Is research chemical DES reliable?
Thomas et al. (2021) documented quality concerns across commercial IGF-1 variant products, including oxidized and degraded forms (PMID 33587816). No pharmaceutical-grade DES exists. Product quality depends entirely on the vendor.
Does IGF-1 DES cause hypoglycemia?
Yes — the same insulin-like glucose-lowering effect as all IGF-1R agonists. The risk may be amplified by post-workout injection timing, when glycogen stores are already depleted and blood glucose may be low.
Is IGF-1 DES detectable in drug testing?
Yes. Validated high-resolution mass spectrometry detection methods exist (PMID 33587816). WADA prohibits des(1-3)IGF-1 under category S2.
Summary of Key Findings
IGF-1 DES is the short-acting sibling of LR3-IGF-1 — same IGFBP evasion, same ~2.5x potency enhancement, same well-characterized IGF-1R signaling, but with a dramatically different pharmacokinetic profile. The ~20–30 minute half-life has carved out a unique community niche: localized muscle injection immediately after training, relying on rapid clearance to concentrate the growth signal at the injection site.
The pharmacological logic is coherent and the foundational animal data is solid. The compound has the additional distinction of being a naturally occurring form — detected in human brain tissue and bovine colostrum — rather than a purely engineered variant. But endogenous presence in trace concentrations does not validate exogenous injection at pharmacological doses.
The evidence gaps are identical to LR3: zero human trials, zero published safety data for exogenous administration, zero dose-finding studies, and documented quality concerns with commercial products. The shorter half-life provides a theoretical safety advantage (less cumulative systemic exposure per dose), but this advantage has never been quantified and is offset by the higher peak concentration at the injection site.
The gut trophic effect documented by Lemmey et al. represents a genuinely interesting therapeutic avenue that has been entirely overlooked — a reminder that the compound's potential extends beyond performance enhancement, even if that's where community interest has focused.
PLAIN ENGLISH
IGF-1 DES works through real biochemistry and has genuine pharmacological rationale behind the site-specific injection protocol. But "the logic makes sense" is not the same as "it's been proven to work." Nobody has tested it in humans, the cancer risk applies to every IGF-1R agonist, and the product you buy isn't pharmaceutical grade. The shorter half-life is a modest advantage, not a safety guarantee.
Verdict Recapitulation
Same rationale as LR3: well-characterized mechanism, pharmacologically coherent, but zero human safety or efficacy data. The shorter half-life and endogenous origin modestly distinguish DES from LR3 on the risk side, but not enough to change the fundamental assessment — no human has been studied using this compound, and the IGFBP evasion that makes it potent is the same property that makes it risky.
For readers considering IGF-1 DES, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source IGF-1 DES
Further Reading and Resources
If you want to go deeper on IGF-1 DES, the evidence landscape for performance & body composition peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Performance & Body Composition Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: IGF-1 DES — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Francis GL, Ross M, Ballard FJ, et al. (1992). "Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGFBPs in IGF-I activity." J Mol Endocrinol, 8(3), 213–223. PMID 2280209
- Tomas FM, Knowles SE, Owens PC, et al. (1992). "Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats." Biochem J, 282(1), 91–97. PMID 1371669
- Lemmey AB, Martin AA, Read LC, et al. (1991). "IGF-I and the truncated analogue des-(1-3)IGF-I enhance growth in rats after gut resection." Am J Physiol, 260(2 Pt 1), E213–E219. PMID 1996625
- Thomas A, Thevis M. (2021). "Analysis of insulin-like growth factor-1 variants by high-resolution mass spectrometry for doping control purposes." Drug Test Anal, 13(4), 866–874. PMID 33587816
- Yoshida T, Delafontaine P. (2020). "Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy." Cells, 9(9), 1970. PMID 32858949
- Jenkins PJ, Mukherjee A, Shalet SM. (2006). "Does growth hormone cause cancer?" Clin Endocrinol, 64(2), 115–121. PMC: 7913862
DISCLAIMER
IGF-1 DES is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 11, 2026. Next scheduled review: October 08, 2026.
About the Author
Lawrence Winnerman
Founder of Peptidings.com. Former big tech product manager. Independent peptide researcher focused on translating clinical evidence into accessible science.